Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures (2016 - 2018)
Historic Gains from Sales and Divestitures for Teva Pharmaceutical Industries (TEVA) over the last 10 years, with Q4 2018 value amounting to $1.6 million.
- Teva Pharmaceutical Industries' Gains from Sales and Divestitures fell 1305.73% to $1.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.6 million, marking a year-over-year decrease of 1305.73%. This contributed to the annual value of $1.6 million for FY2018, which is 1305.73% down from last year.
- According to the latest figures from Q4 2018, Teva Pharmaceutical Industries' Gains from Sales and Divestitures is $1.6 million, which was down 1305.73% from $1.9 million recorded in Q4 2017.
- Over the past 5 years, Teva Pharmaceutical Industries' Gains from Sales and Divestitures peaked at $1.9 million during Q4 2017, and registered a low of -$1.1 million during Q4 2015.
- In the last 5 years, Teva Pharmaceutical Industries' Gains from Sales and Divestitures had a median value of $1.1 million in 2014 and averaged $877200.0.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 19703.32% in 2015, then skyrocketed by 17464.03% in 2016.
- Over the past 5 years, Teva Pharmaceutical Industries' Gains from Sales and Divestitures (Quarter) stood at $1.1 million in 2014, then crashed by 197.03% to -$1.1 million in 2015, then surged by 174.64% to $830000.0 in 2016, then soared by 126.99% to $1.9 million in 2017, then decreased by 13.06% to $1.6 million in 2018.
- Its Gains from Sales and Divestitures stands at $1.6 million for Q4 2018, versus $1.9 million for Q4 2017 and $830000.0 for Q4 2016.